Published in Obstet Gynecol on November 01, 2009
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol (2010) 1.44
Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol (2013) 1.10
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf (2010) 0.92
Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging (2011) 0.82
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther (2010) 0.81
Cancel the denosumab holiday. Osteoporos Int (2016) 0.76
Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone. Clin Rheumatol (2010) 0.75
Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis. Patient Prefer Adherence (2010) 0.75
Intravenous zoledronate for osteoporosis: less might be more. Ther Adv Musculoskelet Dis (2016) 0.75
Zoledronic acid infusion for prevention and treatment of osteoporosis. Int J Womens Health (2010) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science (2011) 3.16
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res (2004) 2.23
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res (2009) 2.22
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc (2010) 2.19
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab (2002) 2.15
Natural stimuli evoke dynamic sequences of states in sensory cortical ensembles. Proc Natl Acad Sci U S A (2007) 2.11
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone (2007) 1.97
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone (2007) 1.94
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther (2007) 1.73
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res (2010) 1.54
The morphologic left ventricle that requires training by means of pulmonary artery banding before the double-switch procedure for congenitally corrected transposition of the great arteries is at risk of late dysfunction. J Thorac Cardiovasc Surg (2008) 1.43
Phonology and reading: a response to Wang, Trezek, Luckner, and Paul. Am Ann Deaf (2009) 1.42
Bone mineral density, hip bone geometry, and calcaneus trabecular bone texture in obese and normal-weight children. J Clin Densitom (2013) 1.39
Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. Stem Cells (2008) 1.32
Viagra use in a community-recruited sample of men who have sex with men, San Francisco. J Acquir Immune Defic Syndr (2003) 1.29
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol (2013) 1.27
Heterogenous population coding of a short-term memory and decision task. J Neurosci (2010) 1.24
Sooner and healthier: a randomised controlled trial and interview study of an early discharge rehabilitation service for older people. Age Ageing (2004) 1.20
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol (2008) 1.18
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res (2009) 1.17
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res (2007) 1.16
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc (2010) 1.16
A randomised controlled trial of a care home rehabilitation service to reduce long-term institutionalisation for elderly people. Age Ageing (2004) 1.15
The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin (2004) 1.15
A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res (2011) 1.14
Body odor similarity in noncohabiting twins. Chem Senses (2005) 1.13
A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc Natl Acad Sci U S A (2006) 1.13
Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol (2013) 1.09
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res (2010) 1.08
Bone mineral density in prepubertal obese and control children: relation to body weight, lean mass, and fat mass. J Bone Miner Metab (2008) 1.06
Relative importance of lean and fat mass on bone mineral density in a group of adolescent girls and boys. Eur J Appl Physiol (2008) 1.06
Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res (2011) 1.05
Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro. Clin Cancer Res (2006) 1.04
Maintaining the trust of physicians and the public in the medical literature: report of a task force on scientific publishing of clinical trials. J Bone Miner Res (2007) 1.03
Total body, lumbar spine and hip bone mineral density in overweight adolescent girls: decreased or increased? J Bone Miner Metab (2009) 1.02
Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells. Mol Cancer Ther (2005) 1.02
Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res (2014) 1.01
Phosphorothioate oligonucleotides block the VDAC channel. Biophys J (2007) 1.01
The spectrum of paediatric cardiac disease presenting to an outpatient clinic in Malawi. BMC Res Notes (2013) 1.01
Midterm results after restoration of the morphologically left ventricle to the systemic circulation in patients with congenitally corrected transposition of the great arteries. J Thorac Cardiovasc Surg (2003) 1.00
Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res (2010) 0.99
Innominate venous aneurysm presenting as a rapidly expanding mediastinal mass. Ann Thorac Surg (2007) 0.99
Three-dimensional characterization of cortical bone microstructure by microcomputed tomography: validation with ultrasonic and microscopic measurements. J Orthop Sci (2007) 0.98
Anisotropy changes in post-menopausal osteoporosis: characterization by a new index applied to trabecular bone radiographic images. Osteoporos Int (2005) 0.97
G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis. Clin Cancer Res (2009) 0.96
Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res (2004) 0.95
Synaptic plasticity and connectivity requirements to produce stimulus-pair specific responses in recurrent networks of spiking neurons. PLoS Comput Biol (2011) 0.95
Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause (2003) 0.95
Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. J Nutr (2007) 0.94
Effects of long-term tennis playing on the muscle-bone relationship in the dominant and nondominant forearms. Can J Appl Physiol (2005) 0.93
Excitatory, inhibitory, and structural plasticity produce correlated connectivity in random networks trained to solve paired-stimulus tasks. Front Comput Neurosci (2011) 0.93
Modulation of Golgi-associated microtubule nucleation throughout the cell cycle. Cytoskeleton (Hoboken) (2012) 0.93
Effects of degraded sensory input on memory for speech: behavioral data and a test of biologically constrained computational models. Brain Res (2010) 0.93
Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc (2011) 0.92
Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. Clin Cancer Res (2004) 0.92
Prospective assessment of thoracic kyphosis in postmenopausal women with osteoporosis. J Bone Miner Res (2010) 0.91
Cooled transurethral microwave thermotherapy for intractable chronic prostatitis--results of a pilot study after 1 year. Urology (2004) 0.91
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab (2009) 0.91
Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT. Bone (2011) 0.90
Hydrolyzed collagen improves bone metabolism and biomechanical parameters in ovariectomized mice: an in vitro and in vivo study. Bone (2009) 0.90
Short-term and long-term site-specific effects of tennis playing on trabecular and cortical bone at the distal radius. J Bone Miner Metab (2006) 0.88
The influence of pulmonary artery morphology on the results of operations for major aortopulmonary collateral arteries and complex congenital heart defects. J Thorac Cardiovasc Surg (2004) 0.87
Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol (2009) 0.87
Devising global strategies for fracture-risk evaluation. Joint Bone Spine (2007) 0.87
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone (2011) 0.87
Phosphorothioate oligonucleotides reduce mitochondrial outer membrane permeability to ADP. Am J Physiol Cell Physiol (2006) 0.86
Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis (2007) 0.86
Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat(®), for age-related macular degeneration. Hum Gene Ther (2012) 0.86
Infant mortality and air pollution: modifying effect by social class. J Occup Environ Med (2004) 0.86
Combined effects of exercise and propranolol on bone tissue in ovariectomized rats. J Bone Miner Res (2007) 0.86
Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol (2011) 0.86
Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev (2016) 0.86
Aging and luteinizing hormone effects on reactive oxygen species production and DNA damage in rat Leydig cells. Biol Reprod (2013) 0.85
Evaluation of macrostructural bone biomechanics. Joint Bone Spine (2007) 0.85
Rivastigmine in Alzheimer disease: efficacy over two years. Am J Geriatr Psychiatry (2004) 0.84
Modeling the atmospheric transport and deposition of mercury to the Great Lakes. Environ Res (2004) 0.84
Osteocalcin-insulin relationship in obese children: a role for the skeleton in energy metabolism. Clin Endocrinol (Oxf) (2011) 0.84
Oxytocin, a new determinant of bone mineral density in post-menopausal women: analysis of the OPUS cohort. J Clin Endocrinol Metab (2014) 0.83
Gene targeting by triple helix-forming oligonucleotides. Ann N Y Acad Sci (2003) 0.83
Positive influence of long-lasting and intensive weight-bearing physical activity on hip structure of young adults. J Clin Densitom (2011) 0.83
Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma. Clin Cancer Res (2004) 0.82